CDKN2A and neoplasm: Last, we observed that the relative size of the tumor-stroma interface in relation to the total tumor volume correlated strongly with poorer outcomes and was significantly associated with disease progression (median OS: 13 months vs. 136, p <0.0001 and median PFS: 5 months vs. 85 months, p<0.0001) which was particularly found in p16-negative tumors (median OS: 15 months vs. 28 months, p <0.03 and median PFS: 6 months vs. 8 months, p<0.05).